Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Unknown 15Completed 13Recruiting 10Active not recruiting 5Terminated 4Withdrawn 3Suspended 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Breast Neoplasms 849Carcinoma, Non-Small-Cell Lung 551Neoplasms 509Prostatic Neoplasms 501Lung Neoplasms 313Colorectal Neoplasms 307Multiple Myeloma 289Neoplasm Metastasis 251Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 209Pancreatic Neoplasms 206Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 164Stomach Neoplasms 162Recurrence 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 151Glioblastoma 147Uterine Cervical Neoplasms 144Head and Neck Neoplasms 141Lymphoma, Non-Hodgkin 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 114Lymphoma, Follicular 112

Interventions

paricalcitol 1ivosidenib 1Taxes 1Neoadjuvant Therapy 1Losartan 1Hydroxychloroquine 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic Ductal Adenocarcinoma × Clear all
NCT05365893 2026-05-22

PHL Treatment in Pancreatic Cancer

Fox Chase Cancer Center

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05846516 2026-04-01

A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer

Boehringer Ingelheim

Phase 1 Active not recruiting
58 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05634720 2026-01-26

Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer

Duke University

Phase 4 Active not recruiting
20 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05209074 2025-09-05

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
16 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT04827953 2024-12-30

NUMANTIA

Nelum Corp

Phase 1/2 Active not recruiting
28 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡